Novel Drug Delivery Systems (NDDS)

Global Market Trajectory & Analytics

MCP13631

EXECUTIVE ENGAGEMENTS

* Login for a full stack data experience

DATE

APR 2021

TABLES

36

131

EDITION

7

PRICE

USD 4950

*Engagement stats are ongoing and dynamic

HIGHLIGHTS

Amid the COVID-19 crisis, the global market for Novel Drug Delivery Systems (NDDS) estimated at US$7.7 Billion in the year 2020, is projected to reach a revised size of US$27.2 Billion by 2027, growing at aCAGR of 19.7% over the period 2020-2027. Nanoparticles, one of the segments analyzed in the report, is projected to record 19% CAGR and reach US$23.2 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Embolization Particles segment is readjusted to a revised 24.7% CAGR for the next 7-year period.

The Novel Drug Delivery Systems (NDDS) market in the U.S. is estimated at US$2.3 Billion in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$4.8 Billion by the year 2027 trailing a CAGR of 19.3% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 17.4% and 16.8% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 13.8% CAGR.

SELECT PLAYERS

Abbott Laboratories; AstraZeneca PLC; Bayer HealthCare Pharmaceuticals; F. Hoffmann-La Roche AG; GlaxoSmithKline PLC; Johnson & Johnson; Merck & Co., Inc.; Novartis International AG; Pfizer, Inc.

SEGMENTS

» Segment (Nanoparticles, Embolization Particles)

GEOGRAPHIES

» World » United States » Canada » Japan » China » Europe » France » Germany » Italy » United Kingdom » and Rest of Europe » Asia-Pacific » Rest of World

I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW

Influencer Market Insights

World Market Trajectories

Impact of Covid-19 and a Looming Global Recession

2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS

4. GLOBAL MARKET PERSPECTIVE

World Current & Future Analysis for Novel Drug Delivery Systems (NDDS) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR

World 7-Year Perspective for Novel Drug Delivery Systems (NDDS) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2020 & 2027

World Current & Future Analysis for Nanoparticles by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR

World 7-Year Perspective for Nanoparticles by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027

World Current & Future Analysis for Embolization Particles by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR

World 7-Year Perspective for Embolization Particles by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027

III. MARKET ANALYSIS

UNITED STATES

USA Current & Future Analysis for Novel Drug Delivery Systems (NDDS) by Segment - Nanoparticles and Embolization Particles - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR

USA 7-Year Perspective for Novel Drug Delivery Systems (NDDS) by Segment - Percentage Breakdown of Value Sales for Nanoparticles and Embolization Particles for the Years 2020 & 2027

CANADA

Canada Current & Future Analysis for Novel Drug Delivery Systems (NDDS) by Segment - Nanoparticles and Embolization Particles - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR

Canada 7-Year Perspective for Novel Drug Delivery Systems (NDDS) by Segment - Percentage Breakdown of Value Sales for Nanoparticles and Embolization Particles for the Years 2020 & 2027

JAPAN

Japan Current & Future Analysis for Novel Drug Delivery Systems (NDDS) by Segment - Nanoparticles and Embolization Particles - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR

Japan 7-Year Perspective for Novel Drug Delivery Systems (NDDS) by Segment - Percentage Breakdown of Value Sales for Nanoparticles and Embolization Particles for the Years 2020 & 2027

CHINA

China Current & Future Analysis for Novel Drug Delivery Systems (NDDS) by Segment - Nanoparticles and Embolization Particles - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR

China 7-Year Perspective for Novel Drug Delivery Systems (NDDS) by Segment - Percentage Breakdown of Value Sales for Nanoparticles and Embolization Particles for the Years 2020 & 2027

EUROPE

Europe Current & Future Analysis for Novel Drug Delivery Systems (NDDS) by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR

Europe 7-Year Perspective for Novel Drug Delivery Systems (NDDS) by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2020 & 2027

Europe Current & Future Analysis for Novel Drug Delivery Systems (NDDS) by Segment - Nanoparticles and Embolization Particles - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR

Europe 7-Year Perspective for Novel Drug Delivery Systems (NDDS) by Segment - Percentage Breakdown of Value Sales for Nanoparticles and Embolization Particles for the Years 2020 & 2027

FRANCE

France Current & Future Analysis for Novel Drug Delivery Systems (NDDS) by Segment - Nanoparticles and Embolization Particles - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR

France 7-Year Perspective for Novel Drug Delivery Systems (NDDS) by Segment - Percentage Breakdown of Value Sales for Nanoparticles and Embolization Particles for the Years 2020 & 2027

GERMANY

Germany Current & Future Analysis for Novel Drug Delivery Systems (NDDS) by Segment - Nanoparticles and Embolization Particles - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR

Germany 7-Year Perspective for Novel Drug Delivery Systems (NDDS) by Segment - Percentage Breakdown of Value Sales for Nanoparticles and Embolization Particles for the Years 2020 & 2027

ITALY

Italy Current & Future Analysis for Novel Drug Delivery Systems (NDDS) by Segment - Nanoparticles and Embolization Particles - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR

Italy 7-Year Perspective for Novel Drug Delivery Systems (NDDS) by Segment - Percentage Breakdown of Value Sales for Nanoparticles and Embolization Particles for the Years 2020 & 2027

UNITED KINGDOM

UK Current & Future Analysis for Novel Drug Delivery Systems (NDDS) by Segment - Nanoparticles and Embolization Particles - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR

UK 7-Year Perspective for Novel Drug Delivery Systems (NDDS) by Segment - Percentage Breakdown of Value Sales for Nanoparticles and Embolization Particles for the Years 2020 & 2027

REST OF EUROPE

Rest of Europe Current & Future Analysis for Novel Drug Delivery Systems (NDDS) by Segment - Nanoparticles and Embolization Particles - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR

Rest of Europe 7-Year Perspective for Novel Drug Delivery Systems (NDDS) by Segment - Percentage Breakdown of Value Sales for Nanoparticles and Embolization Particles for the Years 2020 & 2027

ASIA-PACIFIC

Asia-Pacific Current & Future Analysis for Novel Drug Delivery Systems (NDDS) by Segment - Nanoparticles and Embolization Particles - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR

Asia-Pacific 7-Year Perspective for Novel Drug Delivery Systems (NDDS) by Segment - Percentage Breakdown of Value Sales for Nanoparticles and Embolization Particles for the Years 2020 & 2027

REST OF WORLD

Rest of World Current & Future Analysis for Novel Drug Delivery Systems (NDDS) by Segment - Nanoparticles and Embolization Particles - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR

Rest of World 7-Year Perspective for Novel Drug Delivery Systems (NDDS) by Segment - Percentage Breakdown of Value Sales for Nanoparticles and Embolization Particles for the Years 2020 & 2027

IV. COMPETITION

Total Companies Profiled: 65

PREVIEW REPORT

YOUR PRIVACY MATTERS!

Our robust permission-based engagement strategy requires a one-time double opt-in and/or re-consent for all users. We will re-establish consent once a year from date of last use. Both these practices exceed GDPR mandates.

What we store: Primary coordinates such as email, company address and phone. In-house developed influencer rank.
How we store: Encrypted and additionally secured by firewalls.
How we use your data: Only to contact you directly. We never share your coordinates with any individual or entity outside our company for any reason.
Privacy queries: Privacy@StrategyR.com

DIFFERENTIATORS

Integrity Trust Transparency

Our research offerings primarily draw upon unique perspectives of participating executives and their experiences in operating and strategy roles. These geo-focused insights enrich our projects .

What we are NOT - Our reports are not editorial exercises of remote analysts’ secondary source fed content that predominantly flood today’s off-the-shelf market report business. (A review of 262 publishers).

WHAT SETS US APART

FULL STACK DATA ACCESS

Primary Research Cluster Data
Influencer Engagement Stats
Evidence of Primary Research
List of Companies Engaged
Hundreds of Pages of Research
Peer Collaborative Interactions
Enterprise Data Exchanges
MarketGlassTM Platform Insider
Geographic Pricing Dynamics
Competitive Shares by Country
Brand Curation & Insights
Domain Expert Pool

Program Transparency: Clients have access to engagement stats of companies and executives. Clients may commission third-party audits of our influencer engagements at their expense.

Primary Research: We have a very successful incentive driven primary research program presenting a rich experience to participating executives. Featured company executives can sign up for a complimentary.

Collaborative Intelligence: Our platform presents a unique features for executives to collaborate with peers across geographies and participate on various product or regional perspectives for a collective unified insider project experience.

Global Brand Intelligence: We present competitive brand intelligence at the company level for players worldwide. Executives from brand owner companies participate to curate each brand for relevance and market presence.

Bespoke Updates: Our peer-to-peer online interactive platform enables client companies to build upon our project data stacks to build bespoke editions for internal sharing and use. Client company can build one complimentary update per year and unlimited updates for additional fee. Bespoke updates are fulfilled within a two-day turnaround.

Enterprise EcoConnect: Discretely bounce off queries to participant pool of executives. We can reach out to our participant pool based on specifics of geographic or domain acumen.

Renowned Support: We pride in our commitment to provide support to our clients. We go beyond the scope of the study to get you timely answers.

Complimentary Updates: Unlike the industry’s published PDF’s that are frozen in time from date of release, our research programs are ongoing and dynamic. Our reports are updated whenever there’s a major event impacting the marketplace. Your license offers seamless updates for one year.

No Fluff: We offer our clients the best CX with clean easy to read content. No verbose fluff. We offer clients full access to the entire stack of hundreds of pages of secondary research feeds used in our project via our online MarketGlass portal.

REPORT PREVIEW